PubRank

Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 26963343)

Published in Am J Pathol on March 08, 2016

Authors

Mutsuki Kuraoka1, En Kimura2, Tetsuya Nagata3, Takashi Okada4, Yoshitsugu Aoki1, Hisateru Tachimori5, Naohiro Yonemoto6, Michihiro Imamura1, Shin'ichi Takeda7

Author Affiliations

1: Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
2: Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
3: Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Neurology and Neurological Science, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
4: Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan.
5: Department of Mental Health Policy and Evaluation, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
6: Department of Psychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
7: Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan. Electronic address: takeda@ncnp.go.jp.

Articles citing this ↘

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Devel Ther (2016) 0.80

Osteopontin is Linked with AKT, FoxO1, and Myostatin in Skeletal Muscle Cells. Muscle Nerve (2017) 0.75

Articles by these authors ⇆

In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther (2010) 1.33

Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet (2016) 0.77

Spatial analysis for regional behavior of patients with mental disorders in Japan. Psychiatry Clin Neurosci (2016) 0.77

Factors affecting prolonged length of stay in psychiatric patients in Japan: A retrospective observational study. Psychiatry Clin Neurosci (2017) 0.75

Families' opinions about caring for patients with psychiatric disorders after involuntary hospitalization in Japan. Int J Soc Psychiatry (2015) 0.75